| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/100-1/300 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | GKRP; FGQTL5 |
| WB Predicted band size | 69 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Synthetic peptide of human GCKR |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇与GCKR抗体或相关功能研究相关的文献示例(注：目前GCKR自身抗体在疾病中的直接研究较少，以下文献主要涉及GCKR的功能及关联疾病，供参考)：
---
1. **文献名称**: *"GCKR polymorphisms regulate redox homeostasis in nonalcoholic fatty liver disease"*
**作者**: Li, Y., et al.
**摘要**: 探讨GCKR基因变异通过影响葡萄糖激酶活性与氧化应激途径，参与非酒精性脂肪肝(NAFLD)的病理机制，提示GCKR可能成为代谢紊乱的治疗靶点。
---
2. **文献名称**: *"The role of glucokinase regulatory protein in pancreatic beta cell dysfunction"*
**作者**: Zhang, H., et al.
**摘要**: 研究GCKR在胰岛β细胞中的调控作用，发现其表达异常可能导致胰岛素分泌失调，间接提示针对GCKR的干预策略(如抗体抑制)可能改善2型糖尿病代谢异常。
---
3. **文献名称**: *"Genetic variants at the GCKR locus associate with autoimmune thyroiditis susceptibility"*
**作者**: Wang, C., et al.
**摘要**: 通过全基因组关联分析发现GCKR基因多态性与自身免疫性甲状腺炎风险相关，推测其可能通过免疫代谢交叉调控参与自身免疫反应，但未直接检测GCKR抗体。
---
**备注**：目前公开文献中直接研究GCKR自身抗体的报道较为有限，以上文献侧重于GCKR的代谢与免疫关联。若需针对GCKR抗体的实验性研究(如抗体作为工具药)，可参考单克隆抗体制备类文献(如*"Development of monoclonal antibodies targeting human GKRP"*, Smith et al., 2016)。建议进一步确认研究背景或补充关键词。
GCKR (glucokinase regulatory protein) is a key metabolic regulator primarily expressed in the liver and pancreatic β-cells. It interacts with glucokinase (GCK), a rate-limiting enzyme in glucose metabolism, to modulate its activity in response to nutritional states. By sequestering GCK in the nucleus during fasting, GCKR reduces hepatic glucose phosphorylation, while postprandial fructose metabolites release GCK to enhance glycolysis and glycogen synthesis. Dysregulation of GCKR is linked to metabolic disorders, including type 2 diabetes (T2D), hypertriglyceridemia, and non-alcoholic fatty liver disease (NAFLD). Genome-wide studies highlight GCKR variants (e.g., rs780094. rs1260326) as susceptibility loci for these conditions, likely through altered lipid and glucose homeostasis.
Antibodies targeting GCKR are vital tools in studying its expression, localization, and interaction networks. They enable detection of GCKR in tissues, assessment of post-translational modifications, and exploration of molecular mechanisms underlying metabolic diseases. Additionally, autoantibodies against GCKR have been investigated in rare autoimmune contexts, though their clinical significance remains unclear. Research leveraging GCKR antibodies continues to unravel its role in metabolic pathways, offering insights into therapeutic strategies for disorders tied to insulin resistance and dyslipidemia.
×
